Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Clinical tool

G-CSF Prophylaxis: Is It Needed?

Primary and secondary prophylaxis with filgrastim or pegfilgrastim by regimen and patient risk

Updated: 27 October 20261 min read2 references

Is primary G-CSF prophylaxis needed? Based on the febrile neutropenia risk of the regimen and patient risk factors (ASCO and EORTC guidelines).

Febrile neutropenia risk of the regimen

This calculator needs JavaScript; the formula and its interpretation are in the text of this page.

An aid for clinicians; it does not replace clinical judgement, local protocols or the drug label. Double-check every result before prescribing.

Rules

  • Primary prophylaxis: when the febrile neutropenia risk of the regimen is about 20% or more [1, 2], and in dose-dense regimens that are not feasible without G-CSF [1].
  • Risk of 10–20%: assess patient risk factors; age 65 or older is the most important [2].
  • Secondary prophylaxis: after febrile neutropenia or dose-limiting neutropenia, when dose reduction would compromise curative treatment [1].
  • G-CSF is not routinely recommended for afebrile neutropenia or with concurrent chest chemoradiation [1].
Dose and timing
DrugDoseTiming
Filgrastim5 µg/kg subcutaneously daily [1]From 24–72 hours after chemotherapy until ANC recovery
Pegfilgrastim6 mg subcutaneously once per cycle [1]24–72 hours after chemotherapy; not on the same day

Common questions

Which regimens carry a 20% or higher risk?

Examples: TAC for breast cancer, dose-dense regimens, escalated BEACOPP and most induction regimens for leukaemia and aggressive lymphoma [2]. The exact risk depends on the population and protocol; the EORTC and NCCN guidelines have full lists.

Are biosimilars effective?

Yes; approved filgrastim and pegfilgrastim biosimilars are equivalent to the originators [1].

References

2 references
Show all references, 2 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline UpdateSmith TJ, Bohlke K, Lyman GH, et al · J Clin Oncol · 2015;33:3199-212
    Study cardDOIPubMed Back to text: 1 2 3 4 5 6 7
  2. 2
    2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursAapro MS, Bohlius J, Cameron DA, et al · Eur J Cancer · 2011;47:8-32
    Study cardDOIPubMed Back to text: 1 2 3

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/gcsf-primary-prophylaxis/

Related pages

27 October 2026 ANC Calculator (Absolute Neutrophil Count) Absolute neutrophil count (ANC) calculator with CTCAE neutropenia grading, the definition of febrile neutropenia and what to do immediately. 27 October 2026 MASCC Score for Febrile Neutropenia MASCC risk index calculator for febrile neutropenia and the criteria for oral outpatient treatment per the ASCO/IDSA guideline. 27 October 2026 CISNE Score in Clinically Stable Febrile Neutropenia CISNE score calculator for clinically stable solid-tumour patients with febrile neutropenia, to select candidates for outpatient treatment.